A, D. F., L, H., A, E., R, T., AJ, C., B, R., . . . MM, A. (2026). TTF-1 Expression in Lung Adenocarcinoma: Clinicopathologic, Genomic, and Immunophenotypic Correlates and Outcomes to Immunotherapy-Based Treatments and KRASG12C Inhibitors. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 103610. https://doi.org/10.1016/j.jtho.2026.103610
Chicago Style (17th ed.) CitationA, Di Federico, et al. "TTF-1 Expression in Lung Adenocarcinoma: Clinicopathologic, Genomic, and Immunophenotypic Correlates and Outcomes to Immunotherapy-Based Treatments and KRASG12C Inhibitors." Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer 2026: 103610. https://doi.org/10.1016/j.jtho.2026.103610.
MLA (9th ed.) CitationA, Di Federico, et al. "TTF-1 Expression in Lung Adenocarcinoma: Clinicopathologic, Genomic, and Immunophenotypic Correlates and Outcomes to Immunotherapy-Based Treatments and KRASG12C Inhibitors." Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2026, p. 103610, https://doi.org/10.1016/j.jtho.2026.103610.
